KP 211Alternative Names: KP-211
Latest Information Update: 05 Feb 2003
At a glance
- Originator Kinetek Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Feb 2003 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 13 Mar 2000 Preclinical development for Cancer in Canada (Unknown route)